MEN1309 is a conjugated antibody combined with a potent cytotoxic agent (ADC).
The target of MEN1309 is a membrane protein which is over-expressed by tumor cells of type-B non-Hodgkin's lymphoma and solid tumors of different histological types (such as certain subgroups of breast cancer).
Through the antigen-binding, MEN1309 is internalized in cancer cells where it releases the toxin. Through this mechanism, MEN1309 exerts a potent and selective cytotoxic activity on tumor cells.
The biotechnological process for the production of MEN1309 has been developed at Menarini Biotech in Pomezia.
MEN1309 has demonstrated an excellent anti-tumoral activity in different experimental xenograft models.
A phase I clinical trial SHUTTLE, in oncological patients is active in 4 European Countries (BE,ES, UK, IT) to identify the Maximum Tolerated Dose of the MEN1309
VISIT OUR CLINICAL TRIALS DATABASE